{"identifier":"/us/usc/t21/s826a","title_num":"21","num":"§ 826a.","heading":"Attorney General report on drug shortages","status":null,"guid":"idc712564e-a9f2-11ec-bee8-e0d8ce96928f","source_credit":"(Pub. L. 112–144, title X, § 1006, July 9, 2012, 126 Stat. 1105.)","seq_in_title":478,"parent_identifier":"/us/usc/t21/ch13/schI/ptC","ancestors":[{"identifier":"/us/usc/t21","level":"title","num":"Title 21—","heading":"FOOD AND DRUGS","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch13","level":"chapter","num":"CHAPTER 13—","heading":"DRUG ABUSE PREVENTION AND CONTROL","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch13/schI","level":"subchapter","num":"SUBCHAPTER I—","heading":"CONTROL AND ENFORCEMENT","status":null,"is_section":false},{"identifier":"/us/usc/t21/ch13/schI/ptC","level":"part","num":"Part C—","heading":"Registration of Manufacturers, Distributors, and Dispensers of Controlled Substances","status":null,"is_section":false}],"xml":"<section xmlns=\"http://xml.house.gov/schemas/uslm/1.0\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns:dc=\"http://purl.org/dc/elements/1.1/\" xmlns:dcterms=\"http://purl.org/dc/terms/\" style=\"-uslm-lc:I80\" id=\"id7da915ca-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s826a\"><num value=\"826a\">§ 826a.</num><heading> Attorney General report on drug shortages</heading>\n<chapeau style=\"-uslm-lc:I11\" class=\"indent0\">Not later than 6 months after <date date=\"2012-07-09\">July 9, 2012</date>, and annually thereafter, the Attorney General shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on the Judiciary of the Senate a report on drug shortages that—</chapeau><paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id7da915cb-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s826a/1\"><num value=\"1\">(1)</num><content> identifies the number of requests received under <ref href=\"/us/usc/t21/s826/h\">section 826(h) of this title</ref> (as added by section 1005 of this Act), the average review time for such requests, the number of requests granted and denied under such section, and, for each of the requests denied under such section, the basis for such denial;</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id7da915cc-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s826a/2\"><num value=\"2\">(2)</num><content> describes the coordination between the Drug Enforcement Administration and Food and Drug Administration on efforts to prevent or alleviate drug shortages; and</content>\n</paragraph>\n<paragraph style=\"-uslm-lc:I12\" class=\"indent1\" id=\"id7da915cd-81bc-11eb-b838-b6993269d559\" identifier=\"/us/usc/t21/s826a/3\"><num value=\"3\">(3)</num><content> identifies drugs containing a controlled substance subject to <ref href=\"/us/usc/t21/s826\">section 826 of this title</ref> when such a drug is determined by the Secretary to be in shortage.</content>\n</paragraph>\n<sourceCredit id=\"id7da915ce-81bc-11eb-b838-b6993269d559\">(<ref href=\"/us/pl/112/144/tX/s1006\">Pub. L. 112–144, title X, § 1006</ref>, <date date=\"2012-07-09\">July 9, 2012</date>, <ref href=\"/us/stat/126/1105\">126 Stat. 1105</ref>.)</sourceCredit>\n<notes type=\"uscNote\" id=\"id7da915cf-81bc-11eb-b838-b6993269d559\">\n<note style=\"-uslm-lc:I74\" role=\"crossHeading\" topic=\"editorialNotes\" id=\"id7da915d0-81bc-11eb-b838-b6993269d559\"><heading class=\"centered\"><b>Editorial Notes</b></heading></note>\n<note style=\"-uslm-lc:I75\" topic=\"referencesInText\" id=\"id7da915d1-81bc-11eb-b838-b6993269d559\">\n<heading class=\"centered smallCaps\">References in Text</heading><p style=\"-uslm-lc:I21\" class=\"indent0\">Section 1005 of this Act, referred to in par. (1), means <ref href=\"/us/pl/112/144/s1005\">section 1005 of Pub. L. 112–144</ref>, which amended <ref href=\"/us/usc/t21/s826\">section 826 of this title</ref>.</p>\n</note>\n<note style=\"-uslm-lc:I76\" topic=\"codification\" id=\"id7da915d2-81bc-11eb-b838-b6993269d559\"><heading class=\"centered smallCaps\">Codification</heading>\n<p style=\"-uslm-lc:I21\" class=\"indent0\">Section was enacted as part of the Food and Drug Administration Safety and Innovation Act, and not as part of the Controlled Substances Act which comprises this subchapter.</p>\n</note>\n<note style=\"-uslm-lc:I74\" role=\"crossHeading\" topic=\"statutoryNotes\" id=\"id7da915d3-81bc-11eb-b838-b6993269d559\"><heading class=\"centered\"><b>Statutory Notes and Related Subsidiaries</b></heading></note>\n<note style=\"-uslm-lc:I87\" topic=\"definitions\" id=\"id7da915d4-81bc-11eb-b838-b6993269d559\">\n<heading class=\"centered smallCaps\">Definition of “Secretary”</heading>\n<p style=\"-uslm-lc:I21\" class=\"indent0\">The term “Secretary” as meaning the Secretary of Health and Human Services, see <ref href=\"/us/pl/112/144/s1001/b\">section 1001(b) of Pub. L. 112–144</ref>, set out as an Effect of Notification note under <ref href=\"/us/usc/t21/s356c\">section 356c of this title</ref>.</p>\n</note>\n</notes>\n</section>","provision":null,"duplicates":[],"release":{"label":"117-102","currency_date":"2022-03-15","congress":117,"law_num":102,"excluded_laws":[],"update_num":null,"seq":261,"is_partial":false,"caveat":null,"titles_affected":["09","16","18","20","21","31","38","41","42","48"],"ingested_titles":[]},"served_from":{"label":"117-102","currency_date":"2022-03-15","congress":117,"law_num":102,"excluded_laws":[],"update_num":null,"seq":261,"is_partial":false,"caveat":null,"titles_affected":["09","16","18","20","21","31","38","41","42","48"],"ingested_titles":[]},"content_first_seen":{"label":"116-314not260not283","currency_date":"2021-01-05","congress":116,"law_num":314,"excluded_laws":[260,283],"update_num":null,"seq":225,"is_partial":true,"caveat":"Current through Public Law 116-314 (01/05/2021), except 116-260, 116-283.","titles_affected":["05","05a","06","15","16","18","21","25","28","31","33","34","42","50","54"],"ingested_titles":[]},"is_exact":true,"note":null}